Promis Neurosciences (PMN)Chief Development Officer bought ~$25K

~$25K

Approx. value · 1,629 sh @ $15.35

3,941

Holds after · shares reported

Traded

Feb 19, 2026

Filed

Feb 23, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 29, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
2. Feb 3, 2026Insider · Largest insider buy since 202210% owner purchased ~$8.5M of PMN shares in the open market
3. Feb 19, 2026 · this disclosureInsider · Their first buy on recordOfficer purchased ~$25K of PMN shares in the open market

What came next

1. Mar 2, 2026Insider · Their largest buy since 2022Director purchased ~$23K of PMN shares in the open market
2. Mar 3, 2026InsiderDirector purchased ~$22K of PMN shares in the open market
3. Mar 4, 2026Insider · Their largest buy since 2022Director purchased ~$48K of PMN shares in the open market
4. Mar 5, 2026InsiderDirector purchased ~$49K of PMN shares in the open market
5. Mar 25, 2026Company filing · Form 8-K · ResultsReported its results
6. Apr 22, 2026Insider · Their largest buy since 2022Director purchased ~$45K of PMN shares in the open market
7. May 12, 2026Company filing · Form 8-K · ResultsReported its results
8. May 20, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“As further described in Item 5.07 below, the stockholders of ProMIS Neurosciences Inc. (the “ Company ”) approved an amendment (the “2025 Plan Amendment”) to the Company’s 2025 Stock Option and Incentive Plan (the “ 2025 Plan ”) at the Company’s 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”) held on May 20, 2026.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Promis Neurosciences

For Promis Neurosciences, OQRO holds 1 insider filing (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PMN page.

Other recent filings by Johanne Kaplan, Chief Development Officer

• SEC Form 4 at Promis Neurosciences (PMN)Aug 8, 2026

The full history of Johanne Kaplan, Chief Development Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Promis Neurosciences

• SEC Form 4Aug 8, 2026
• SEC Form 4Apr 24, 2026
• SEC Form 4Mar 6, 2026
• SEC Form 4Mar 5, 2026
• SEC Form 4Mar 5, 2026
• SEC Form 4Mar 5, 2026

Everything OQRO holds on this company is on its PMN page.